Histopathology-guided mass spectrometry differentiates benign nevi from malignant melanoma.

Journal: Journal of cutaneous pathology
Published Date:

Abstract

PURPOSE: Distinguishing benign nevi from malignant melanoma using current histopathological criteria may be very challenging and is one the most difficult areas in dermatopathology. The goal of this study was to identify proteomic differences, which would more reliably differentiate between benign and malignant melanocytic lesions.

Authors

  • Rossitza Lazova
    Department of Pathology, California Skin Institute, San Jose, California.
  • Katy Smoot
    New River Labs, LLC, Morgantown, West Virginia.
  • Heather Anderson
    New River Labs, LLC, Morgantown, West Virginia.
  • Matthew J Powell
    New River Labs, LLC, Morgantown, West Virginia.
  • Arlene S Rosenberg
    Department of Dermatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.
  • Franco Rongioletti
    Unit of Dermatology, University of Cagliari, Cagliari, Italy.
  • Luca Pilloni
    Section of Pathology, Department of Surgery, University of Cagliari, Cagliari, Italy.
  • Sara D'Hallewin
    Unit of Dermatology, University of Cagliari, Cagliari, Italy.
  • Ralitza Gueorguieva
    Department of Biostatistics, Yale University, New Haven, CT, USA.
  • Iliana Tantcheva-Poór
    Department of Dermatology, University of Cologne, Cologne, Germany.
  • Omobolade Obadofin
    Department of Pathology, Federal Medical Center, Lagos, Nigeria.
  • Christine Camacho
    Department of Pathology, California Skin Institute, San Jose, California.
  • Andy Hsi
    Department of Pathology, California Skin Institute, San Jose, California.
  • Harriet H Kluger
    Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
  • Oluwole Fadare
    Department of Pathology, University of California San Diego, San Diego, California.
  • Erin H Seeley
    New River Labs, LLC, Morgantown, West Virginia.